Cargando…

Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment

PURPOSE: The safety and efficacy of subcutaneous immune globulin 20% (human) solution (Ig20Gly) were demonstrated in clinical trials. However, real-world evidence of the tolerability of self-administered Ig20Gly in elderly patients is lacking. We describe real-world patterns of Ig20Gly usage for 12...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rosenbach, Kevin, Park, Michelle, Sanchirico, Marie, Nwose, Oliseyenum, Paris, Kenneth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275800/ https://www.ncbi.nlm.nih.gov/pubmed/36809598 http://dx.doi.org/10.1007/s10875-023-01436-4

Ejemplares similares

Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases
por: Fasshauer, Maria, et al.
Publicado: (2023)

Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study
por: Keith, Paul K., et al.
Publicado: (2022)

Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study
por: Keith, Paul K., et al.
Publicado: (2023)

Role of Colesevelam in Combination Lipid-Lowering Therapy
por: Jones, Michael R., et al.
Publicado: (2013)

Atypical Mechanism of Glucose Modulation by Colesevelam in Patients with Type 2 Diabetes
por: Nwose, Oliseyenum M., et al.
Publicado: (2013)

Switch from intravenous to subcutaneous immunoglobulin IgPro20 in CIDP patients: a prospective observational study under real-world conditions
por: Gingele, Stefan, et al.
Publicado: (2021)

Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies
por: Canessa, Clementina, et al.
Publicado: (2016)

Cutaquig(®) Is Well Tolerated in Immunodeficient Patients Who Did Not Tolerate Other Subcutaneous Immunoglobulin Products
por: Brownlee, Sydney, et al.
Publicado: (2022)

Real-world evidence of subcutaneous treprostinil use in pulmonary arterial hypertension in Argentina
por: Lescano, Adrián, et al.
Publicado: (2022)

Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies
por: Cinetto, Francesco, et al.
Publicado: (2021)

New Frontiers in Subcutaneous Immunoglobulin Treatment
por: Jolles, Stephen, et al.
Publicado: (2011)

A clinician’s guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases
por: Epland, Kristin, et al.
Publicado: (2022)

Real-World Experiences With Facilitated Subcutaneous Immunoglobulin Substitution in Patients With Hypogammaglobulinemia, Using a Three-Step Ramp-Up Schedule
por: Hustad, Nina B., et al.
Publicado: (2021)

Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency
por: Hagan, John B., et al.
Publicado: (2010)

An evaluation of the budget impact of a new 20% subcutaneous immunoglobulin (Ig20Gly) for the management of primary immunodeficiency diseases in Switzerland
por: Pollock, Richard F, et al.
Publicado: (2018)

Use of subcutaneous immunoglobulin in inflammatory myositis
por: Zhou, Alan L, et al.
Publicado: (2021)

Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency Diseases
por: Kanegane, Hirokazu, et al.
Publicado: (2014)

Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study
por: van Schaik, Ivo N., et al.
Publicado: (2019)

Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy
por: Goyal, Namita A., et al.
Publicado: (2021)

Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig(®)) in the treatment of patients with primary immunodeficiencies
por: Kobayashi, Roger H, et al.
Publicado: (2022)

Response to the Letter to the Editor Regarding “Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials”
por: Suez, Daniel, et al.
Publicado: (2017)

Efficacy and Safety of Hizentra(®), a New 20% Immunoglobulin Preparation for Subcutaneous Administration, in Pediatric Patients with Primary Immunodeficiency
por: Borte, Michael, et al.
Publicado: (2011)

Real-World Adherence and Evidence of Subcutaneous and Sublingual Immunotherapy in Grass and Tree Pollen-Induced Allergic Rhinitis and Asthma
por: Vogelberg, Christian, et al.
Publicado: (2020)

Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
por: Jolles, Stephen
Publicado: (2013)

Replacement and Immunomodulatory Activities of 20% Subcutaneous Immunoglobulin Treatment: A Single-Center Retrospective Study in Autoimmune Myositis and CVID Patients
por: Danieli, Maria Giovanna, et al.
Publicado: (2022)

Scleromyxedema with Subcutaneous Nodules: Successful Treatment with Thalidomide and Intravenous Immunoglobulin
por: Dolenc-Voljč, M., et al.
Publicado: (2013)

Long-term treatment of refractory myasthenia gravis with subcutaneous immunoglobulin
por: Kovács, Edina, et al.
Publicado: (2017)

Subcutaneous Immunoglobulins are a Valuable Treatment Option in Myasthenia Gravis
por: Garnero, Martina, et al.
Publicado: (2018)

Long-term treatment with subcutaneous immunoglobulin in multifocal motor neuropathy
por: Gentile, Luca, et al.
Publicado: (2021)

Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study
por: Borte, Michael, et al.
Publicado: (2023)

Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies
por: Kobayashi, Roger H., et al.
Publicado: (2019)

High-Dose Subcutaneous Immunoglobulins for the Treatment of Severe Treatment-Resistant Polymyositis
por: Patrick, Cherin, et al.
Publicado: (2014)

Subcutaneous immunoglobulins for the treatment of a patient with antisynthetase syndrome and secondary chronic immunodeficiency after anti-CD20 treatment: a case report
por: Cherin, Patrick, et al.
Publicado: (2017)

Improved quality of life with home therapy with subcutaneous immunoglobulins for patients with secondary hypogammaglobulinaemia
por: Levasseur, Marie-Claude, et al.
Publicado: (2012)

Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency
por: Wasserman, Richard L., et al.
Publicado: (2016)

Real‐world performance of the atrial fibrillation monitor in patients with a subcutaneous ICD
por: Baalman, Sarah W.E., et al.
Publicado: (2020)

Systemic reactions to subcutaneous allergen immunotherapy: real-world cause and effect modelling
por: Aue, Adam, et al.
Publicado: (2021)

Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
por: Skoda-Smith, Suzanne, et al.
Publicado: (2010)

Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig(®)]) in the treatment of patients with primary immunodeficiencies
por: Kobayashi, Roger H., et al.
Publicado: (2022)

Automating Access to Real-World Evidence
por: Gauthier, Marie-Pier, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_puko1ag4t1hg8f6c2qams4kiqo